Dare Bioscience Inc
NASDAQ:DARE

Watchlist Manager
Dare Bioscience Inc Logo
Dare Bioscience Inc
NASDAQ:DARE
Watchlist
Price: 2.1958 USD -3.69%
Market Cap: 31.4m USD

Operating Margin
Dare Bioscience Inc

-49 247.3%
Current
-24 979%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-49 247.3%
=
Operating Profit
-13.6m
/
Revenue
27.7k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Dare Bioscience Inc
NASDAQ:DARE
31.8m USD
-49 247%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
500.1B USD
27%
CH
Roche Holding AG
SIX:ROG
257.6B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
24%
CH
Novartis AG
SIX:NOVN
206.1B CHF
33%
US
Merck & Co Inc
NYSE:MRK
249.9B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
142.3B USD
29%
No Stocks Found

Dare Bioscience Inc
Glance View

Market Cap
30.6m USD
Industry
Pharmaceuticals

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2014-04-10. The firm is focused on advancing products for women's health. The company offers a portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. Its first product, XACIATO, is a vaginal gel used for the treatment of bacterial vaginosis in females having 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1, and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-RH1, ADARE-204, and ADARE-214. Ovaprene, is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.

DARE Intrinsic Value
10.0369 USD
Undervaluation 78%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-49 247.3%
=
Operating Profit
-13.6m
/
Revenue
27.7k
What is the Operating Margin of Dare Bioscience Inc?

Based on Dare Bioscience Inc's most recent financial statements, the company has Operating Margin of -49 247.3%.

Back to Top